Celadon Pharmaceuticals Plc (AIM: CEL)

Market Cap	24.41M
Revenue (ttm)	75.00K
Net Income (ttm)	-7.14M
Shares Out	65.98M
EPS (ttm)	-0.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	518,732
Open	47.48
Previous Close	52.50
Day's Range	35.45 - 50.00
52-Week Range	20.00 - 140.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 27, 2024

About Celadon Pharmaceuticals

Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products. Its products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2018
• Employees: 27
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: CEL

Financial Performance

In 2023, Celadon Pharmaceuticals's revenue was 75,000, an increase of 212.50% compared to the previous year's 24,000. Losses were -7.14 million, -58.01% less than in 2022.